Skip to main content

Latest Articles

Latest Articles

Showing 9 / 741 Metabolic Health articles

RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Telehealth & Peptide Therapy

RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift

Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.

Shotlee··6 min read